Join SMi at the 12th annual Pain Therapeutics conference, which will be held on 21^st & 22^nd May 2012 in London, UK.

Pain is an incredibly hot topic as it affects all illnesses and all people, in many different ways. This makes it an incredibly lucrative business and one that has not yet been explored in the pharmaceutical industry to its full potential. Pain is also the most common reason patients seek medical care, as it affects the quality of life many people experience and has significant sensory and emotional components. Whilst advances have been made in pain management, few significant ones have occurred, making it harder in recent years to get analgesics to market.

In the current economic climate, this makes it even more imperative for companies to improve their R&D methods so that drugs being put forward for clinical trials have the best chance of success.

New speaker announcement: Jason Witherington, Head of Chemistry, GlaxoSmithKline will be joining our esteemed panel of speakers to talk about epigenetics in inflammation and beyond.


Hear key presentations from industry-leading experts:

• Chas Bountra, Professor of Translational Medicine, Head, Structural Genomics Centre Oxford University
• Jonathan Stewart, Disease Area Head, Neuroscience, Immunology and Pain, Bristol-Myers Squibb
• Philip Kym, Associate Director II Pain Discovery Research, Abbott
• Mark Bowlby, Neurophysiology and Pain Lead, Merck
• Dave Shelton, Senior Director, Pfizer Global Research & Development
  

 

Network with our registered attendees:

• Mundipharma Research GmbH & Co. KG
• Antwerp University Hospital
• Helsinn Healthcare
• Grünenthal GmbH
• Orion Corporation
• Pfizer Ltd
• Ricerca Biosciences
• Aquila BioMedical
• Esteve
• Astellas Pharma Kft
• NsGene
• University of Bristol
  

Visit www.pain-therapeutics.co.uk for more information or to register your place. Alternatively, contact Jay Clements at Tel: +44 (0)20 7827 6734 or Email: jclements@smi-online.co.uk